ContraFect Announces Additional $2.3 Million in Funding from CARB-X to Support Gram-Negative Lysin Program January 17, 2019
ContraFect’s Exebacase (CF-301) Improved Clinical Outcomes in Staphylococcus aureus Bacteremia including Right-Sided Endocarditis Compared to Standard of Care Antibiotics Alone in a First-in-Patient Phase 2 Superiority Study January 7, 2019
ContraFect to Present at 2nd International Symposium on Antimicrobial Hydrolytic Enzymes November 1, 2018
ContraFect to Present at the “Exploring the Antibiotic Pipeline 2018” Symposium and also to Present New Data on CF-301 (exebacase) at IDWeek 2018 September 25, 2018
